Skip to main content

Dr. Edwin Choy, MD PHD

Medical Oncology (Medical Oncology Physician)

  • Medicare participating

At a glance

Years since graduation
26
In the NPI registry since
2005
Medicare patients seen, 2024
254

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 2000Medical school: New York University School of Medicine
  • 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Medical Oncology Physician primary
    MA license 213868
  • Hematology & Oncology Physician
    MA license 213868

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Medical Oncology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
254
Services billed
1,152
Patients’ average age
73
Most frequent Medicare services, 2023
ServiceTimesPatients
Established patient office or other outpatient visit, 40-54 minutes459196
Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes7331
Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes4223
Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes2320

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Most prescribed drugs, Medicare Part D 2024
DrugPrescriptions
Imatinib Mesylate89
Eliquis (apixaban)
Other prescribers in Boston, MA
32
Sorafenib (sorafenib tosylate)17
Prochlorperazine Maleate
Other prescribers in Boston, MA
17
Dexamethasone
Other prescribers in Boston, MA
14
Ondansetron Hcl
Other prescribers in Boston, MA
14
Sunitinib Malate13
Xarelto (rivaroxaban)
Other prescribers in Boston, MA
12
Lorazepam
Other prescribers in Boston, MA
12
Turalio (pexidartinib hydrochloride)11

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 2 companies reported 9 payments worth $606 in total to this clinician.

By company
Icotec Medical Inc.$437
Ipsen Biopharmaceuticals, Inc$170
By type
Food and Beverage$582
Compensation for services other than consulting (speaking, faculty)$24.00

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Nov 12, 2025Ipsen Biopharmaceuticals, Inc
Nov 12, 2025
Compensation for services other than consulting (speaking, faculty)
Tazverik · Oncology
$24.00

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Massachusetts →

Industry-funded research

Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $8,040 in research payments for these studies, mostly to the institutions running them.

  • Phase I Study of Olaparib and Temozolomide in Patientes with Recurrent Refractory Ewings Sarcoma
    AstraZeneca Pharmaceuticals LP
  • Phase II/III Brigimadlin in 1st L DD Liposarcoma
    Boehringer Ingelheim Pharmaceuticals, Inc.

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Medical Oncology clinicians in Boston

Sources

NPI registry (CMS NPPES, November 2026; record last updated January 26, 2026), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1760466106. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.